1Y Close · As of Aug 26, 2026
NGeneBio operates in the Leasing sector.
Legal name: NGeneBio Co., Ltd.
In fiscal year 2025, NGeneBio (354200) reported revenue of 21.2 billion KRW, up 273.2% from 5.7 billion KRW a year earlier.
Operating profit was -8.3 billion KRW and net income was -6.8 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 16.2 billion KRW, with a P/B of 0.72.
These figures can be verified in the DART filing (receipt no. 20260323001424).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 21.2B | -8.3B | -6.8B |
| 2024 | 5.7B | -16.1B | -13.9B |
| 2023 | 4.4B | -13.4B | -12.9B |
Recent Filings
Derivative Trading Loss
Large Shareholding Report (General)
Officer/Major Shareholder Ownership Report
Checks
5 of 8 checked items currently applicable.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Derivative Trading Loss |
| 2026-08-14 | Large Shareholding Report (General) |
| 2026-08-14 | Officer/Major Shareholder Ownership Report |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-07 | Officer/Major Shareholder Ownership Report |